NANO Nuclear Energy (NNE) Q2 2026 earnings summary

Executive summary

• Advanced the KRONOS MMR system with a formal Construction Permit Application submitted to the U.S. NRC by the University of Illinois, marking a major milestone toward commercialization.

• Completed feasibility studies for up to 1 GW of power for BaRupOn's AI data center, supporting staged large-scale deployments.

• Established strategic partnerships and MOUs with Supermicro, EHC Investment, and DS Dansuk for commercialization, regional deployment, and supply chain localization.

• Progressed vertical integration and supply chain initiatives, including M&A and DOE program participation, to address nuclear fuel and transportation bottlenecks.

• No material revenue generated to date; business remains pre-commercialization.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $569 million as of March 31, 2026, providing robust liquidity.

• Q2 net loss was $9.2 million, up $3 million sequentially but down $12 million year-over-year due to higher interest income and lower equity-based compensation.

• Year-to-date net cash used in operating activities rose by $4 million to $9.3 million, mainly from higher personnel and professional fees.

• Year-to-date net cash used in investing activities increased by $368 million to $381 million, driven by higher short-term investments.

• $900 million shelf registration, including a $400 million ATM facility, became effective, enhancing future financial flexibility.

Outlook and guidance

• Construction at the University of Illinois expected to begin in mid-to-late 2027, pending NRC review.

• Expenses anticipated to rise as the team scales and procurement for long-lead items and testing equipment begins.

• Estimated cash expenditures for fiscal 2026 are $65 million, with $43 million for R&D, $12 million for fuel supply chain, and $10 million for administrative costs.

• Ongoing evaluation of non-dilutive funding opportunities, including government incentives and partnerships.

• Commercial launch of KRONOS MMR targeted for early 2030s, pending regulatory approvals.